Consequently, starting with adjuvant aromatase inhibitors is recommended, especially for patients with more aggressive disease due to higher stage (e.g., stage III) or tumor biology (e.g., high Ki-67 in luminal B subtypes) [26,27,28]. Here, CYP19A1 is linked to neoplasm.